FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091283140> ?p ?o ?g. }

• W2091283140 endingPage "333" @default.
• W2091283140 startingPage "326" @default.
• W2091283140 abstract "We have earlier shown an advantage in overall survival for malignant lymphoma (ML) patients who received combined Interleukin-2 (rIL-2) and interferon alpha (IFN-alpha) immunotherapy after autologous stem cell transplantation (AutoSCT) in comparison with historic controls. On the basis of these results, we initiated a control prospective randomized multicenter 2-arm study, comparing the same combined immunotherapy treatment versus control for patients with malignant lymphoma after AutoSCT. One hundred nine patients were included in this study. After AutoSCT, patients were randomized either to the treatment group or to the control group. Patients in the treatment group received daily subcutaneous injections of rIL-2 6x10 IU/m/d for 5 consecutive days followed by 2-weeks rest period. Subsequently, they were treated daily with rIL-2 6x10 IU/m/d combined with INF-alpha 3x10 U/d for 5 consecutive days per week for 4 consecutive weeks. After 4 weeks of rest, IFN-alpha 3x10 U was administered for the next 6 months 3 times per week. Patients in the control group were followed up at the outpatient clinic. There was a significant enhancement of survival (P=0.05) and a clear trend in disease-free survival in favor of NHL patients receiving post-AutoSCT immunotherapy, in comparison with the control group. Eighty-nine percent of patients with NHL treated with immunotherapy were alive and 64% were disease free. In the control group, 66% of patients survived and 46% were disease free. Among the HL patients no significant differences were observed regarding survival, disease-free survival, and relapse rate. No serious toxicity events were observed. These results suggest that outpatient administered immunotherapy with IFN-alpha and rIL-2 is relatively well tolerated and may intensify remission in NHL patients, but not HL patients after AutoSCT." @default.
• W2091283140 created "2016-06-24" @default.
• W2091283140 creator A5020301140 @default.
• W2091283140 creator A5022864146 @default.
• W2091283140 creator A5030282008 @default.
• W2091283140 creator A5034694882 @default.
• W2091283140 creator A5042016815 @default.
• W2091283140 creator A5045116114 @default.
• W2091283140 creator A5058925624 @default.
• W2091283140 creator A5062199973 @default.
• W2091283140 creator A5080589501 @default.
• W2091283140 creator A5082078271 @default.
• W2091283140 date "2010-04-01" @default.
• W2091283140 modified "2023-10-18" @default.
• W2091283140 title "A Randomized Controlled Multicenter Study Comparing Recombinant Interleukin 2 (rIL-2) in Conjunction With Recombinant Interferon Alpha (IFN-α) Versus no Immunotherapy for Patients With Malignant Lymphoma Postautologous Stem Cell Transplantation" @default.
• W2091283140 cites W1492996678 @default.
• W2091283140 cites W1548609628 @default.
• W2091283140 cites W1911320760 @default.
• W2091283140 cites W1914489852 @default.
• W2091283140 cites W1929276460 @default.
• W2091283140 cites W1937560614 @default.
• W2091283140 cites W1955081269 @default.
• W2091283140 cites W1978772118 @default.
• W2091283140 cites W1987319895 @default.
• W2091283140 cites W1992964537 @default.
• W2091283140 cites W1997353354 @default.
• W2091283140 cites W2011319944 @default.
• W2091283140 cites W2016420042 @default.
• W2091283140 cites W2017044710 @default.
• W2091283140 cites W2021588881 @default.
• W2091283140 cites W2022759117 @default.
• W2091283140 cites W2025950737 @default.
• W2091283140 cites W2034834856 @default.
• W2091283140 cites W2038465924 @default.
• W2091283140 cites W2043369632 @default.
• W2091283140 cites W2043799126 @default.
• W2091283140 cites W2048127039 @default.
• W2091283140 cites W2048483756 @default.
• W2091283140 cites W2058015212 @default.
• W2091283140 cites W2078052929 @default.
• W2091283140 cites W2081025478 @default.
• W2091283140 cites W2082888406 @default.
• W2091283140 cites W2100404595 @default.
• W2091283140 cites W2104066024 @default.
• W2091283140 cites W211185702 @default.
• W2091283140 cites W2122887099 @default.
• W2091283140 cites W2123437098 @default.
• W2091283140 cites W2178727026 @default.
• W2091283140 cites W2260370664 @default.
• W2091283140 cites W2297816245 @default.
• W2091283140 cites W2300937173 @default.
• W2091283140 cites W2333306614 @default.
• W2091283140 cites W2407389866 @default.
• W2091283140 cites W64930248 @default.
• W2091283140 doi "https://doi.org/10.1097/cji.0b013e3181c810b6" @default.
• W2091283140 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20445353" @default.
• W2091283140 hasPublicationYear "2010" @default.
• W2091283140 type Work @default.
• W2091283140 sameAs 2091283140 @default.
• W2091283140 citedByCount "14" @default.
• W2091283140 countsByYear W20912831402012 @default.
• W2091283140 countsByYear W20912831402013 @default.
• W2091283140 countsByYear W20912831402014 @default.
• W2091283140 countsByYear W20912831402015 @default.
• W2091283140 countsByYear W20912831402016 @default.
• W2091283140 countsByYear W20912831402017 @default.
• W2091283140 countsByYear W20912831402018 @default.
• W2091283140 crossrefType "journal-article" @default.
• W2091283140 hasAuthorship W2091283140A5020301140 @default.
• W2091283140 hasAuthorship W2091283140A5022864146 @default.
• W2091283140 hasAuthorship W2091283140A5030282008 @default.
• W2091283140 hasAuthorship W2091283140A5034694882 @default.
• W2091283140 hasAuthorship W2091283140A5042016815 @default.
• W2091283140 hasAuthorship W2091283140A5045116114 @default.
• W2091283140 hasAuthorship W2091283140A5058925624 @default.
• W2091283140 hasAuthorship W2091283140A5062199973 @default.
• W2091283140 hasAuthorship W2091283140A5080589501 @default.
• W2091283140 hasAuthorship W2091283140A5082078271 @default.
• W2091283140 hasConcept C121608353 @default.
• W2091283140 hasConcept C126322002 @default.
• W2091283140 hasConcept C141071460 @default.
• W2091283140 hasConcept C168563851 @default.
• W2091283140 hasConcept C203014093 @default.
• W2091283140 hasConcept C204243189 @default.
• W2091283140 hasConcept C2776178377 @default.
• W2091283140 hasConcept C2777701055 @default.
• W2091283140 hasConcept C2779050716 @default.
• W2091283140 hasConcept C2779338263 @default.
• W2091283140 hasConcept C2781228144 @default.
• W2091283140 hasConcept C2909179924 @default.
• W2091283140 hasConcept C2911091166 @default.
• W2091283140 hasConcept C535046627 @default.
• W2091283140 hasConcept C71924100 @default.
• W2091283140 hasConcept C90924648 @default.
• W2091283140 hasConceptScore W2091283140C121608353 @default.
• W2091283140 hasConceptScore W2091283140C126322002 @default.
• W2091283140 hasConceptScore W2091283140C141071460 @default.
• W2091283140 hasConceptScore W2091283140C168563851 @default.

• next